Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO
May 16, 2016 16:01 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (“Syndax” or the “Company”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in...
Syndax to Announce First Quarter 2016 Financial Results and Host Conference Call and Live Webcast on May 16, 2016
April 26, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2016 financial results on Monday, May 16, 2016, after the closing of...
Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
April 11, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer...
Syndax Announces Pricing of Initial Public Offering
March 02, 2016 18:28 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications,...